TABLE 3.

Coronary Aneurysm Response (mITT Population)

Change Description	Etanercept (N = 98),a n (%)	Placebo (N = 99),b n (%)	Pc
Change from maximum to visit 5
CA change
Better	56 (57)	53 (54)	.86
No change	32 (33)	36 (36)
Worse	10 (10)	10 (10)
CA improvement
Improved	56 (57)	53 (54)	.61
Unchanged or worse	42 (43)	46 (46)
Aneurysm improvement
Improved	2 (50)	3 (37.5)	1.00
Unchanged or worse	2 (50)	5 (62.5)
Change from baseline to visit 5
CA change, all
Better	42 (43)	41 (41)	.83
No change	36 (37)	34 (34)
Worse	20 (20)	24 (24)
CA change, base CA dilation
Better	15 (63)	14 (64)	.03
No change	7 (29)	1 (5)
Worse	2 (8)	7 (32)
CA change, no base CA dilation
Better	27 (37)	27 (36)	.91
No change	28 (38)	32 (42)
Worse	18 (25)	17 (22)

^aFour subjects in the mITT population had no postbaseline echocardiographic measurements.

^bCA dilation is defined as a z score ≥2.5 in any artery or any aneurysm at baseline.

^cP values from the t test for continuous variables and the χ² test for categorical variables.